preview china focu
get better
look achiev tavr spine micra av off-set
competit challeng diabet ahead
coronaviru headwind like weigh china asid
investor like stay focus pipelin
diabet key overhang
look achiev model in-lin street revenu
pt sequenti momentum deceler stack basi
number reflect momentum stabil see exhibit may
appropri metric normal comp follow outag
hurrican maria note thu far earn seen pt
weighted-averag deceler across coverag bp deceler
adjust bd om model bp y/i improv
indic modest y/i improv slight fx
headwind reach ep in-lin street bp
upsid top-line growth bp om tax
bp model low-end guidanc could collect
worth addit ep
exhibit guidanc impli slight momentum acceler
impli
china focu china medtron sale nearli
come cvg expect materi impact coronaviru
given case escal mid-januari vs jan quarter-end
manufactur sale could expos recent commentari
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
see bd see indic risk like remain
highlight similar impact boston expect
china sale lost would impact
worth bp growth bp corpor growth
increment diversifi busi rel
boston china impact could vari china impact
acceler thesi stock thesis-alt longer term
china price anoth element worth consid see tail risk
convinc meaning impact
cvg model organ growth in-lin street
last full quarter dcb headwind
could deliv mid-teen sequenti dcb growth support peer
commentari bd dcb revenu rose sequenti
manag also signal share loss sequenti dcb
growth worth increment revenu
reflect model tavr may deliv inflect
immedi follow low-risk expans report
similar growth rate edward could see
upsid lvad like return growth given
abbott heartmat launch anniversari late octob micra av
launch sens sale possibl
see
rtg model organ growth vs street
upsid spine like base market momentum zimmer
show sever point acceler
robot implant pull capit stealthstat o-arm mazor
stealth strong momentum stabil spine follow
strength would mean potenti upsid drive
bp rtg bp corpor model above-market
growth hsd vs msd market gener
posit share gain look forward vs db see within
specialti therapi could see slight downsid mse current
reflect impact axon given axon deliv
revenu indic continu strength earli
januari see
mitg model organ growth vs
model continu reflect pt momentum acceler vs
saw steril headwind surgic innov
earli year manag rais mitg midpoint
last quarter support momentum
acceler remaind year driven steril
advanc energi advanc stapl includ newer colorect
diabet model organ growth slightli
street model meet guidanc flat-to-slightly-down
organ growth reflect competit dynam us new patient
renew total dg revenu manag cite call
call look updat new pump deferr program
ahead pivot data come ada june recent
becom interest tandem control-iq
omnipod though continu model dg organ growth
convinc number fulli de-risk flat year
diabet would current model bp
earn rais light china less like need
increment revenu bridg impli top-end guidanc
seeexhibit growth year tavr
micra av spine sourc
upsid china uncertainti on-going competit challeng diabet
potenti make guidanc rais unlik continu
see greater likelihood acceler support pipelin
assum top-line growth in-lin guidanc would need
deliv bp om expans vs bp tax low-
end guidanc vs model reach ep
growth year note manag lower tax guidanc
past two quarter bp bp respect indic tax may
still conserv china high impact scenario bp corpor
top-line growth see could worth ep
ceo transit remain focu last quarter omar
ishrak leadership geoff martha becom ceo april see
understand geoff alreadi taken activ role strateg
decis make note although predict recent analysi
ceo transit across coverag sinc indic stock
modestli under-perform medic devic transit outperform
follow transit see possibl receiv increment
commentari geoff strateg prioriti although expect
like come june analyst day expect qualit
comment geoff vision believ busi grow faster
futur expect specif quantif new lrp metric
june analyst day
net see slightli less posit risk-reward quarter risk reward
perhap littl less posit preview prior quarter
given clear opportun top-line upsid
although anticip top-line guidanc rais earlier year
would expect rais point given dynam discuss overal
remain comfort result see risk china
lesser extent diabet viru impact china materi
debate-alt longer term investor remain focus pipelin
on-going low-risk tavr inflect micra av see ardian data shown
march surgic robot expect launch ex-u late
month us said diabet pressur china
deriv base case scenario price target reflect base-cas
ep discount larg cap peer total return profil
long-term profil mid-singl digit organ growth bp
margin expans high-singl digit ep growth total return profil
risk price target includ materi competit landscap chang
db tavr dcb linq ii slowdown acceler emerg market
iii less repurchas activ materi acquisit
exhibit impli organ growth guid base segment guidanc
end guid
top end guid
million except ep
good sold
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
prepaid expens current asset
addit paid capit
accumul non-own chang equiti
receiv employe stock ownership plan
dollar million except per share data
depreci amort
net chg work capit
net provid oper activ
acquisit net cash acquir
net use invest activ
chang debt
chang equiti net tax benefit
begin period
end period
